Fractyl Health (NASDAQ:GUTS - Get Free Report)'s stock had its "buy" rating reissued by investment analysts at HC Wainwright in a note issued to investors on Friday,Benzinga reports. They presently have a $8.00 price target on the stock.
Several other research analysts have also weighed in on GUTS. Morgan Stanley lowered Fractyl Health from an "overweight" rating to an "equal weight" rating and lowered their price objective for the stock from $8.00 to $2.00 in a research report on Thursday, January 29th. Weiss Ratings reiterated a "sell (d-)" rating on shares of Fractyl Health in a research report on Monday, December 29th. Finally, Canaccord Genuity Group restated a "buy" rating and set a $8.00 price target on shares of Fractyl Health in a research note on Thursday, March 26th. Three analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of "Hold" and a consensus target price of $5.40.
Get Our Latest Analysis on Fractyl Health
Fractyl Health Trading Down 1.6%
Shares of Fractyl Health stock opened at $0.58 on Friday. The firm has a market capitalization of $92.18 million, a price-to-earnings ratio of -0.32 and a beta of 1.20. Fractyl Health has a fifty-two week low of $0.38 and a fifty-two week high of $3.03. The company has a debt-to-equity ratio of 3.23, a quick ratio of 4.78 and a current ratio of 4.78. The stock has a 50 day moving average of $0.48 and a 200 day moving average of $1.19.
Fractyl Health (NASDAQ:GUTS - Get Free Report) last issued its quarterly earnings data on Tuesday, March 24th. The company reported $0.15 earnings per share for the quarter, topping the consensus estimate of ($0.19) by $0.34. As a group, research analysts predict that Fractyl Health will post -0.67 earnings per share for the current year.
Institutional Trading of Fractyl Health
Several hedge funds have recently modified their holdings of the stock. Bank of America Corp DE raised its stake in shares of Fractyl Health by 23.5% in the third quarter. Bank of America Corp DE now owns 88,634 shares of the company's stock valued at $141,000 after acquiring an additional 16,856 shares in the last quarter. Jane Street Group LLC acquired a new stake in shares of Fractyl Health in the second quarter valued at $31,000. FNY Investment Advisers LLC acquired a new stake in shares of Fractyl Health in the third quarter valued at $31,000. Jump Financial LLC acquired a new stake in shares of Fractyl Health in the fourth quarter valued at $57,000. Finally, Scientech Research LLC acquired a new stake in shares of Fractyl Health in the third quarter valued at $49,000.
Fractyl Health Company Profile
(
Get Free Report)
Fractyl Health, Inc is a clinical-stage medical technology company focused on the development and commercialization of minimally invasive, endoscopic therapies for metabolic diseases. Headquartered in Lexington, Massachusetts, Fractyl is advancing treatments that target the underlying physiology of conditions such as type 2 diabetes, obesity and nonalcoholic fatty liver disease (NAFLD) by modifying the duodenal mucosa to improve metabolic control.
The company's lead product, Revita® Duodenal Mucosal Resurfacing (Revita DMR), employs a catheter-based hydrothermal ablation technique to remodel the lining of the upper small intestine.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Fractyl Health, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Fractyl Health wasn't on the list.
While Fractyl Health currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
We are about to experience the greatest A.I. boom in stock market history...
Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.
That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.
- The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
- The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
- Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.
Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.
And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...
Simply click the link below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
